Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Special Report
Generics' last days in top-earning product group
PBS stats released this week show that although most of the top performing products are branded, brands don't completely rule the roost, especially among the top five but when October price cuts take full effect, things will be different.
Open Forum
Community pharmacy won't be a theory victim says PM
Prime Minister Tony Abbott told the Pharmacy Guild's annual dinner he is a strong supporter of community pharmacy and 'won't promote theory over practice' when it comes to managing the health budget. Here's what he said in full.
Pipeline Monitor
Novartis scores in psoriasis
Novartis' new first-in-class psoriasis treatment Cosentyx has been recommended for approval in Europe while BI continues to do battle with Roche in bringing new IPF drugs to market.
Approvals Action
Lantus biosimilar threatens $140m market
Abasria Eli Lilly's biosimilar competitor for Sanofi's Lantus has been approved by the TGA, threatening the $140 million market held by the leading diabetes product.
Special Report
Who's growing fastest on the PBS?
At the end of Q2 14-15, two companies stood out among the top PBS earners for growth that outpaces the average, thanks to highly successful drug launches in 2012 and 2013 but change could be afoot in the next 12 months.
Working Life
Gender equality: why Merck Serono is a winner
Merck Serono's appearance on the inaugural Employer of Choice for Gender Equality list is not by chance, gender equality is something the company 'lives and breathes' says MD Andre Musto.